Schedule 13G ownership disclosure

VERTEX PHARMACEUTICALS INC COM

Security class unavailable · CUSIP: 92532F100

Event date: 2017-12-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
28,338,859
Percent of class
11.2000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000080255-18-002365
Form type
SC 13G/A
Filer
PRICE T ROWE ASSOCIATES INC /MD/
CIK
CIK 80255
Filed
Feb 14, 2018
Reporting period
Dec 31, 2017
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub